美沙拉嗪口服联合中药灌肠治疗溃疡性结肠炎临床观察(1)
 |
| 第1页 |
参见附件(1309KB，2页)。
【摘要】 目的 观察美沙拉嗪口服联合中药灌肠治疗溃疡性结肠炎的临床疗效。方法 65例患者随机分为治疗组35例,用美沙拉嗪口服联合中药保留灌肠,对照组30例用SASP口服及保留灌肠,观察两组临床症状、结肠黏膜的改善情况及不良反应。结果 治疗组和对照组的总有效率分别为94.3%和73.3%,两组临床疗效比较有显著性差异(P<0.05),治疗组症状及结肠黏膜的改善情况优于对照组(P<0.05),治疗组与对照组的不良反应比较有高度显著性差异(P<0.01)。结论 美沙拉嗪口服联合中药保留灌肠治疗溃疡性结肠炎安全有效。
【关键词】 溃疡性结肠炎;美沙拉嗪;中西医结合;保留灌肠
Curative effects of mesalazine PO in combination with Chinese medicine enema on treatment of ulcerative colitis
HUANG Pingfu,LIU Shouzhi.
Chuzhou City’s Hospital of Integrated Traditional and Western Medicine,Chuzhou,239000,China
【Abstract】 Objective To investigate the clinical efficacy of mesalazine PO in combination with Chinese medicine enema on ulcerative colitis(UC).Methods 65 patients were randomly divided into two groups.The 35 in treatment group were treated with mesalazine PO and Chinese medicine retention enema.The other 30 in control group were treated with SASP PO as well as retention enema.The differences of clinical symptoms,the variation of colonic mucosa and adverse reactions were observed before and after the treatment.Results The total effective rate in treatment group and control group was 94.3%and 73.3%respectively.The clinical efficacy of two groups was significant difference(P<0.05).The improvement of symptoms and colonic mucosa was superior than the control group(P<0.05).There was a very significant difference between treatment group and control group in adverse drug reactions.(P<0.01).Conclusion Mesalazine PO in combination with Chinese medicine enema has a safe and obvious therapeutic efficacy on ulcerative colitis.
【Key words】 Ulcerative colitis;Mesalazine;Integrated traditional and western medicine;Retention enema
溃疡性结肠炎(ulcerative colitis,UC)是一种迄今具体病因欠明的特发于大肠黏膜和黏膜下层的慢性非特异性炎症,以腹泻、腹痛、黏液脓血便和里急后重为主症。本病与中医的“大瘕泻”相似,归属于“泄泻”、“肠风”等范畴[1]。2008年10月至2010年5月,我们采用口服美沙拉嗪肠溶片联合中药保留灌肠治疗UC35例,并进行对照观察,取得较好疗效,现报告如下。
1 资料与方法
1.1 一般资料
65例UC患者均为我院门诊及住院患者,其中轻度24例,中度36例,重度5例,随机分为两组:治疗组35例,男17例,女18例,年龄20~62岁,平均36.9岁,病程4个月至21年,平均(7.4±6.8)年,病变位于直肠者10例,直、乙状结肠者21例,乙状结肠以上者4例。对照组30例,男14例,女16例,年龄21~59岁,平均35.6岁,病程3个月至19年,平均(7.1±6.6)年,病变位于直肠者8例,直、乙状结肠者19例,乙状结肠以上者3例。两组间的性别、年龄、病程、病变范围等差异均无统计学意义(P>0 ......
您现在查看是摘要介绍页，详见PDF附件(1309KB，2页)。